[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"central-nervous-system-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:central-nervous-system-diseases":788},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,35,0,25,[9,38,67,111,141,169,199,276,295,313,346,374,407,437,490,521,539,572,603,625,662,683,708,740,759],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100443617",false,"NCT05056740","Combined Analysis of Inflammatory Biomarkers for CNS Autoimmune Diseases Diagnostic","Evaluation of a Combined Analysis of Serum and Cerebrospinal Fluid Inflammatory Biomarkers to Help in Etiological Diagnosis of Central Nervous System Autoimmune Diseases","CyBIRD","Inclusion Criteria:\n\n* Patients referred to our center for the diagnostic work-up of White Matter Lesions\n* Patients that need a routine blood analysis\n* Patients that need a routine CSF analysis\n* Non opposition to research consent\n\nExclusion Criteria:\n\n* Patients with a contraindication to perform spinal tap (increase bleeding risk medicine or disease)\n* Patients with a contraindication to MRI (metal prosthesis…)","ALL",{"count":19,"type":20},300,"ESTIMATED","OBSERVATIONAL","Project rationale:\n\nSince 2017, multiple sclerosis diagnosis should match the new McDonald criteria in which a \"no better explanation than MS\" should be fulfilled. However, many patients present with red flags that lead to a complex diagnostic work-up. There are no available biomarkers that permit to confirm or roll out MS diagnosis in such cases. Therefore, we lack biological markers that can help in the diagnosis of patients presenting with suspected MS.\n\nMany studies have found that serum and cerebrospinal fluid (CSF) cytokines could help to differentiate MS from other diseases such as neuromyelitis optica spectrum disorders (i.e., IL-6) or neurosarcoidosis (i.e., sIL-2R). Serum and CSF kappa free light chains have also shown good diagnosis performance in MS. In daily practice, our MS tertiary center already perform the analysis of CSF concentrations of IL-1β, sIL-2R, IL-6, IL-10, and serum and CSF kappa and lambda free light chains to roll out other central nervous system (CNS) autoimmune diseases in patients presenting with white matter hyperintensities (WMH).\n\nObjective:\n\nTo correlate CSF IL-1β, sIL-2R, IL-6, IL-10, serum and CSF kappa and lambda free light chains with the final diagnosis in patients presenting to our MS tertiary center with suspected MS to identify a specific inflammatory biomarker profil involved in MS and other CNS autoimmune diseases.\n\nThe methodology:\n\nThis is an observational study. All patients ongoing a routine diagnostic work-up for suspected MS from june 2020 to june 2022 in our MS tertiary center will be analyzed. Cerebrospinal fluid IL-1β, sIL-2R, IL-6, IL-10, serum and CSF kappa and lambda free light chains will be correlated with the final diagnosis to ultimately find MS associated biomarkers.",[24],"Central Nervous System Diseases","RECRUITING","2026-06-25",{"date":28,"type":29},"2026-06-26","ACTUAL",{"date":31,"type":29},"2020-06-01",{"date":33,"type":20},"2027-06-25",{"name":35,"class":36},"Centre Hospitalier Universitaire de Nice","OTHER",1,{"id":39,"slug":4,"hasResults":11,"nctId":40,"briefTitle":41,"officialTitle":41,"acronym":42,"eligibilityCriteria":43,"healthyVolunteers":11,"sex":17,"minAge":44,"maxAge":45,"enrollmentInfo":46,"targetDuration":4,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":37},"100520211","NCT06053619","Tolerance Study of Robotic-Assisted Virtual Reality Walking Rehabilitation for Non-Walking Stroke Patients","RAVIS","Inclusion Criteria:\n\n* Hemiparesis following a first ischemic or hemorrhagic stroke;\n* subacute phase (15 days to 6 months);\n* Aged 35 to 75 years;\n* Non-walking subject (unable to walk 3 x 10 meters without human assistance or Functional Ambulation Classification ≤ 2);\n* Benefiting from robot-assisted walking rehabilitation in the readaptation and physical medecin department of the Limoges University Hospital;\n* Having the cognitive abilities to understand and follow simple verbal instructions (MMSE \\\u003C 24 or BDAE \\\u003C 2)\n* Be able to give informed consent to participate in this study.\n\nExclusion Criteria:\n\n* Have neurological and psychiatric conditions, other than stroke;\n* Conditions contraindicating the use of virtual reality (e.g., epileptic disorders, major cerebellar syndrome).\n* Inability to evolve in a virtual environment (MSSQ-Short \\> 26)\n* Patient with acute cardiovascular and respiratory disorders;\n* Patient who is subject to a legal protection measure or who is unable to give consent;\n* Person deprived of liberty\n* Person with high VR experience during the 5 years before stroke\n* pregnant woman, breastfeeding woman","35 Years","75 Years",{"count":47,"type":20},30,"INTERVENTIONAL",[50],"NA","The primary objective of this study is to evaluate the tolerance of the use of immersive virtual reality (VR) during robotic walking rehabilitation sessions by Gait Trainer (GT) in post-stroke patients.\n\nSecondary objectives aim to evaluate the motivation to participate in VR sessions compared to conventional sessions, the participants' sense of presence within the virtual environment, and the usability of the rehabilitation device created. Finally, we will report the actual walking time and number of steps stroke patients take in VR sessions and conventional sessions.",[53,24],"Stroke",[53,55,56,57,58],"Virtual Reality","Stroke Rehabilitation","Robotic","Gait Trainer","2026-06-24",{"date":26,"type":29},{"date":62,"type":29},"2023-11-20",{"date":64,"type":20},"2027-03-11",{"name":66,"class":36},"University Hospital, Limoges",{"id":68,"slug":4,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":17,"minAge":73,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":48,"phases":76,"briefSummary":78,"conditions":79,"keywords":86,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":110},"100618049","NCT07326566","Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII","A Phase 2 Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Silevertinib, an Oral EGFR Inhibitor, in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter and EGFRvIII","Key Inclusion Criteria:\n\n* Newly diagnosed histologically confirmed glioblastoma that is isocitrate dehydrogenase wild type (IDH-WT).\n* Positive EGFR status in the brain tumor as determined by a commercially available test or validated laboratory assay (CLIA or comparable certification).\n* For Part 1 (Safety Lead-in) ONLY: EGFR alterations.\n* For Part 2 (Randomized, Controlled Trial) ONLY: EGFRvIII.\n* For Part 2 (Randomized, Controlled Trial) ONLY: Unmethylated MGMT promoter tumor status based on a validated assay.\n* No treatment for newly diagnosed GBM other than surgery followed by standard-of-care adjuvant postoperative radiation (54 to 60 Gy) and TMZ chemotherapy.\n* At least 4 weeks since completion of radiation therapy, with a post-radiation MRI showing no progression.\n\nKey Exclusion Criteria:\n\n* Recurrent multifocal disease, metastatic, leptomeningeal, or extracranial GBM, or gliomatosis cerebri.\n* Progression of GBM prior to Enrollment, Screening, or Randomization.\n* Biopsy-only\u002Fno resectional surgery.\n* Prior or concomitant treatment for GBM with an EGFR-targeting agent, including silevertinib, bevacizumab, cytotoxic chemotherapy, immunotherapy, experimental therapies, Gliadel wafers, GammaTile®, or other intratumoral or intracavitary antineoplastic therapy.\n* Intent to use Optune® (TTF).\n* Significant other uncontrolled health conditions or other malignancies.","18 Years",{"count":75,"type":20},162,[77],"PHASE2","The purpose of this study is to see if combining silevertinib with temozolomide after surgery and radiotherapy helps treat newly diagnosed glioblastoma (GBM) better than using temozolomide alone in the maintenance setting.\n\nSpecifically, this study is being done to find answers to the following questions:\n\n* How much of the study drugs (silevertinib combined with temozolomide) should be given to participants with GBM?\n* What are the side effects participants have when taking the study drug (silevertinib combined with temozolomide)?\n* Can the study drug (silevertinib combined with temozolomide) help participants with GBM live longer without disease progression compared to treatment with temozolomide alone?",[80,81,82,83,84,24,85],"Glioblastoma (GBM)","Newly Diagnosed Glioblastoma","GBM","Glioblastoma Multiforme (GBM)","Glioma","Brain Cancer",[87,88,89,90,91,92,93,94,95,96,97,98,99],"EGFR","Glioblastoma","Unmethylated","Unmethylated MGMT promoter","Newly Diagnosed","temozolomide","Temodar","silevertinib","BDTX-1535","EGFR alterations","epidermal growth factor receptor","EGFRvIII","epidermal growth factor receptor (EGFR)","2026-06-18",{"date":102,"type":29},"2026-06-22",{"date":104,"type":29},"2026-05-05",{"date":106,"type":20},"2029-03",{"name":108,"class":109},"Black Diamond Therapeutics, Inc.","INDUSTRY",14,{"id":112,"slug":4,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":17,"minAge":73,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":48,"phases":120,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":140},"100468924","NCT05386108","Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+\u002FHER-2- Breast Cancer","An Open-label Multicenter Phase 1b-2 Study of Elacestrant in Combination With Abemaciclib in Women and Men With Brain Metastasis From Estrogen Receptor Positive, HER-2 Negative Breast Cancer","ELECTRA","Inclusion Criteria:\n\n1. Participant has the signed informed consent form before any study-related activities according to local guidelines.\n2. Women or men aged ≥18 years, at the time of informed consent signature.\n\n   * Female participants may be either postmenopausal or pre\u002Fperimenopausal. Postmenopausal status is defined by:\n\n     1. Age ≥60 years\n     2. Age \\\u003C60 years and amenorrhea for 12 or more months without an alternative cause) and follicle stimulating hormone and estradiol in postmenopausal ranges per local reference ranges\n     3. Documentation of prior bilateral oophorectomy, at least 1 month before first dose of trial therapy).\n   * Pre-menopausal \u002F peri-menopausal women and men must be concurrently receiving a luteinizing hormone-releasing hormone (LHRH) agonist starting at least 3-4 weeks before the start of trial therapy and is planning to continue LHRH during the study.\n3. Participant must have ER-positive, HER-2 negative tumor status as confirmed by local laboratory testing in the following manner:\n\n   * Documentation of ER positive tumor with ≥ 1% staining by immunohistochemistry (IHC) as defined in the 2010 or 2020 American Society for Clinical Oncology (ASCO) recommendations for ER testing, with or without progesterone receptor (PGR) positivity\n   * HER-2 negative tumor with an IHC result of 0 or 1+ for cellular membrane protein expression or an in situ hybridization negative result as defined in the 2013 or 2018 ASCO recommendations for HER-2 testing\n4. In Phase 2, participants must have at least one active and measurable brain metastasis per RECIST version 1.1.\n\n   * Any of the following qualifies brain metastases as active:\n\n     1. Newly diagnosed brain metastasis in participants who never received prior central nervous system (CNS)-directed therapy.\n     2. Newly diagnosed brain metastasis outside any area that was previously subjected to CNS-directed therapy.\n     3. Brain metastases demonstrating unequivocal progression in the opinion of the treating investigator in an area that has previously been subjected to CNS-directed therapy.\n   * For lesions, including brain metastases, to qualify as measurable, and possibly be selected as target lesions, per RECIST version 1.1, the longest diameter must be ≥10 millimeters \\[mm\\] by computed tomography \\[CT\\] or magnetic resonance imaging \\[MRI\\]).\n   * In Phase 1b, the presence of brain metastases is allowed but not required for eligibility, in this case, at least 1 measurable lesion outside the brain is required.\n5. Participants receiving concomitant corticosteroids must be on a stable or decreasing dose for at least 7 days prior to baseline and not receiving doses higher than 4 mg of dexamethasone per day or equivalent.\n6. Participants have experienced no more than one seizure within 4 weeks prior to starting trial therapy.\n7. Participants' prior therapy received in the metastatic setting includes:\n\n   * At least one endocrine therapy\n   * Up to two chemotherapy regimens\n   * Up to two lines of prior cyclin-dependent kinase (CDK) 4\u002F6 inhibitor, not including abemaciclib\n\n   Note 1: Toxicity from prior therapy must be resolved to NCI CTCAE version 5.0 Grade ≤1, with the exception of alopecia and peripheral sensory neuropathy (Grade ≤2).\n\n   Note 2: Chemotherapy refers to not targeted cytotoxic agents (for example, alkylating agents, taxanes, nucleotide analogs, platinum-based drugs, vinca alkaloids, etc) and antibody drug conjugates (ADCs). Targeted therapies (for example, kinase inhibitors) are not considered chemotherapy for eligibility purposes. Not targeted cytotoxic agents administered for less than 1 cycle will not be counted as a prior chemotherapy regimen.\n8. Participant has documented intracranial and\u002For extracranial radiological progression or recurrence while on or after the most recent therapy.\n9. Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤2\n10. Participant has a life expectancy ≥ 12 weeks.\n11. Participant has adequate bone marrow and organ function, as defined by the following laboratory values:\n\n    1. Absolute neutrophil count (ANC) ≥1.5 × 10\\^9\u002Fliter (L)\n    2. Platelets ≥100 × 10\\^9\u002FL\n    3. Hemoglobin ≥9.0 grams (g)\u002Fdeciliter (dL)\n    4. Potassium, sodium, calcium (corrected for serum albumin) and magnesium CTCAE Grade ≤1 (if screening assessments are abnormal, these assessments may be repeated up to 2 times; participants may receive appropriate supplementation or treatment prior to reassessment)\n    5. Creatinine clearance (per Cockcroft-Gault formula) ≥50 mL\u002Fminute\n    6. Serum albumin ≥3.0 g\u002FdL (≥30 g\u002FL)\n    7. Liver function tests:\n\n       In absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3.0 × upper limit of normal (ULN). If the participant has liver metastases, ALT and AST ≤5.0 × ULN.\n    8. Total serum bilirubin \\\u003C1.5 × ULN except for participants with Gilbert's syndrome who may be included if the total serum bilirubin is ≤3.0 × ULN or direct bilirubin ≤ 1.5 × ULN\n12. The participant is willing and able to adhere to the study visit schedule and other protocol requirements.\n\nExclusion Criteria:\n\n1. Immediate CNS-specific treatment is likely to be required, per the treating physician's assessment.\n2. Participant has imminent organ failure and\u002For visceral crisis.\n3. Participant has leptomeningeal metastases, defined as having positive cerebrospinal fluid (CSF) cytology or unequivocal radiologic and clinical evidence of leptomeningeal involvement. Note: Discrete dural metastases are permitted.\n4. Breast cancer treatment-naïve participants (that is, not having received any systemic therapy) in the advanced\u002Fmetastatic setting.\n5. History of pulmonary embolism (PE), cardiovascular accident (CVA), myocardial infarction (MI) in the past 6 months from screening visit.\n6. Prior therapy with abemaciclib in the metastatic setting. Note: Use of abemaciclib in the adjuvant setting is allowed if the last treatment administration was more than 12 months prior to first recurrence.\n7. Prior therapy with elacestrant or other investigational selective estrogen receptor degraders (SERDs), or investigational alike agents such as selective estrogen receptor modulators (SERMs), selective estrogen receptor covalent antagonists (SERCANs), complete estrogen receptor antagonists (CERANs), and proteolysistargeting chimeras (PROTACs) in the metastatic setting.\n8. Participant has a concurrent malignancy or malignancy within 3 years of enrollment, with the exception of adequately treated basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix, or second primary breast cancer; and any other malignancy that is considered in complete remission by the Investigator(s) that is approved by the Medical Monitor.\n9. Currently participating in another breast cancer intervention clinical study. Participants who are being followed for overall survival for another clinical trial with no therapy and study intervention are allowed after the washout period for any prior therapy.\n10. Prior anti-cancer or investigational drug treatment within the following windows:\n\n    * Fulvestrant treatment (last injection) \\\u003C42 days before first dose of study drug\n    * Any other endocrine therapy \\\u003C14 days before first dose of study drug. Note: LHRH agonists should not be counted as endocrine therapy.\n    * Chemotherapy or other anti-cancer therapy \\\u003C14 days before first dose of study drug\n    * Any investigational anti-cancer drug therapy within \\\u003C28 days or \\\u003C5 half lives, whichever is shorter\n    * Bisphosphonates or receptor activator of nuclear factor-κB ligand (RANKL) inhibitors initiated, or dose changed \\\u003C1 month prior to first dose of study drug according to institutional guidelines.\n11. Radiation therapy (including CNS directed) within 7 days before the first dose of study drug or without a full recovery from radiotherapy acute effects.\n12. Uncontrolled significant active infections\n\n    * Participants with hepatitis B virus (HBV) and\u002For hepatitis C virus (HCV) infection must have undetectable viral load (or detected below the lower limit of quantification) during screening\n    * Participants known to be human immunodeficiency virus positive (HIV+) are allowed as long as they have undetectable viral load (viral suppression) at baseline.\n13. Major surgery within 4 weeks of starting trial therapy.\n14. Inability to take oral medication, or history of malabsorption syndrome or any other uncontrolled gastrointestinal condition that may significantly alter the absorption of study drugs.\n15. Females of childbearing potential who do not agree to use a highly effective non-hormonal method of contraception and to abstain from donating ova within 28 days of the first dose of study treatment through 120 days after the last dose of study treatment. Highly effective non-hormonal method of contraception includes any of the following:\n\n    1. Intrauterine device (non-hormonal)\n    2. Sexual abstinence\n    3. Bilateral tubal occlusion\u002Fligation\n    4. Have a vasectomized partner with confirmed azoospermia.\n16. Male participants (including males after a vasectomy) with a pregnant or non-pregnant female of childbearing potential partner who do not agree to use a highly effective barrier contraception method (condoms) within 28 days of the first dose of study treatment until 120 days of the last dose of study treatment. And male participants who do not agree to abstain from freezing or donating sperm within the same period. In addition, female partners of childbearing potential, of male participants (who has not undergone vasectomy) must use highly effective methods of contraception.\n17. Females who are pregnant or breastfeeding. Females should not get pregnant during study treatment and for 120 days after last dose of study treatment. Females should not breastfeed during administration of elacestrant and for 1 week after receiving the last dose.\n18. Known intolerance to either study drug or any of their excipients.\n19. Participants currently receiving or received any of the following medications prior to first dose of trial therapy:\n\n    1. Known strong or moderate inducers or inhibitors of cytochrome P450 (CYP) 3A4 (including foods and herbal preparations) within 14 days or \\\u003C5 half-lives, whichever is shorter)\n    2. Herbal preparations\u002Fmedications (which are not strong or moderate inducers or inhibitors of CYP3A4). These include, but are not limited to, kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, and ginseng within 7 days prior to initiating trial therapy\n    3. Vaccination, including but not limited to vaccination against coronavirus disease-19 (COVID-19), during the 7 days prior to randomization.\n20. Any severe medical or psychiatric condition that in the opinion of the investigator(s) would preclude the participant's participation in a clinical study.",{"count":119,"type":20},73,[121,77],"PHASE1","This is a multi-site, global, open-label study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain metastases from estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER-2) negative breast cancer. Phase 1b was designed to select the recommended phase 2 dose (RP2D) and is followed by an ongoing phase 2 evaluation of elacestrant in combination with abemaciclib in participants with active brain metastases from ER-positive, HER-2 negative breast cancer.",[124,125,126,127,128,129,130,24],"Breast Neoplasms","Brain Neoplasms","Neoplasms by Site","Neoplasms","Breast Diseases","Central Nervous System Neoplasms","Brain Diseases","2026-06-03",{"date":133,"type":29},"2026-06-04",{"date":135,"type":29},"2022-08-31",{"date":137,"type":20},"2026-12",{"name":139,"class":109},"Stemline Therapeutics, Inc.",86,{"id":142,"slug":4,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":148,"sex":17,"minAge":149,"maxAge":150,"enrollmentInfo":151,"targetDuration":4,"studyType":48,"phases":153,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":37},"100384501","NCT04286516","Brain Connections for Arm Movement After Stroke","Brain Areas That Control Reaching Movements After Stroke: Task-relevant Connectivity and Movement-synchronized Brain Stimulation","CAM","Inclusion Criteria:\n\nInclusion Criteria (control participants):\n\n* Be 45-90 years of age\n* Have adequate language and neurocognitive function to participate in training and testing\n* Be medically stable to participate in the study\n* Be English speaking\n\nInclusion Criteria (participants with stroke):\n\n* Be 45-90 years of age\n* Clinically defined, unilateral, hemiparetic stroke with radiologic exclusion of other possible diagnosis\n* Stroke onset at least 6 months before enrollment\n* Subcortical stroke (ex: internal capsule, deep white matter of posterior frontal lobe)\n* Present with mild to moderate arm dysfunction\n* Be medically stable to participate in the study\n* Be English speaking\n\nExclusion Criteria:\n\n(for both groups)\n\n* Unable to give informed consent\n* Have a serious complicating medical illness that would preclude participation\n* Contractures or orthopedic problems limiting range of joint motion in the potential study arm or other impairments that would interfere with the study activities\n* Visual loss such that the subject would not be able to see the test patterns on the robot computer monitor\n* Unable to comply with requirements of the study\n* Enrollment in another greater-than-minimal risk study\n* Presence of medical condition or implant that prevents safe administration of TMS or MRI\n* Pregnancy",true,"45 Years","90 Years",{"count":152,"type":20},76,[50],"The purpose of this study is to use Transcranial Magnetic Stimulation (TMS) while subjects are making reaching movements in a robotic arm device in order to discover how different brain areas control movement before and after stroke and when these brain areas are most sensitive to TMS.",[53,156,24,157,158],"Brain Disease","Nervous System Diseases","Cardiovascular Diseases","2026-05-28",{"date":161,"type":29},"2026-06-02",{"date":163,"type":29},"2020-01-10",{"date":165,"type":20},"2027-06-01",{"name":167,"class":168},"VA Office of Research and Development","FED",{"id":170,"slug":4,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":17,"minAge":73,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":48,"phases":177,"briefSummary":179,"conditions":180,"keywords":184,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":198},"100507832","NCT05892510","Post-thrombectomy Intra-arterial Tenecteplase for Acute manaGement of Non-retrievable Thrombus and No-reflow in Emergent Stroke","Post-thrombectomy Intra-arterial Tenecteplase for Acute manaGement of Non-retrievable Thrombus and No-reflow in Emergent Stroke (EXTEND-AGNES TNK)","Inclusion Criteria:\n\n* Adult participants (age≥18 years) presenting with ischemic stroke with arterial LVO on CT\u002FMR Angiogram of the intracranial internal carotid or middle cerebral artery (MCA) first segment (M1) or proximal second segment (M2) committed to thrombectomy using standard criteria within 24 hours of onset:\n* For 0-6 hours of symptom onset: Presence of arterial occlusion as defined above and ASPECTS≥3 on NCCT\n* For 6-24 hours of symptom onset: Additional imaging criteria on CTP or MRI perfusion of core volume \\\u003C100ml.\n* Qualifying CT\u002FMR within 4hrs of randomisation (repeat CT for transferred participants required if \\>4hr)\n* Pre-stroke Modified Rankin Scale (mRS) score of ≤2 (mild pre-existing disability permitted)\n* Local legal requirements for consent have been satisfied.\n\nExclusion Criteria:\n\n* Intracranial hemorrhage identified by CT or MRI\n* ASPECTS 0-2 on NCCT\n* CTP or MRI perfusion ischemic core volume \\>100ml if presenting within 6-24 hours from symptoms onset\n* Anticipated endovascular stenting required for intracranial or extracranial atherosclerotic stenosis\u002Focclusion.\n* More than six retrieval attempts in the same vessel\n* Alteplase being infused within 30 minutes (\\~5x half-life) of anticipated trial drug administration\n* Contraindication to imaging with contrast agents\n* Any condition (eg.mid-arterial phase early venous filling) that in the judgment of investigators could impose hazards if study therapy is initiated\n* Pregnant women.\n* Current participation in another intervention research study that includes experimental interventions beyond standard-of-care.\n* Anticoagulation. INR ≤1.7 if on warfarin, and dabigatran reversal by idarucizumab are permitted.\n* Other standard contraindications to thrombolysis apart from time window.\n* Known terminal illness such that the participants would not be expected to survive a year.\n* Planned withdrawal of care or comfort care measures.",{"count":176,"type":20},462,[77,178],"PHASE3","Multicentre, prospective, Multi-arm Multi-stage (MAMS) seamless phase 2b\u002F3 interventional randomized placebo-controlled double-blinded parallel-assignment (2 arms with 1:1 randomization) efficacy and safety trial to test intra-arterial tenecteplase at the completion of thrombectomy versus best practice in participants with anterior circulation LVO receiving mechanical thrombectomy within 24 hours of symptoms onset.",[181,182,183,24],"Ischemic Stroke, Acute","Cerebrovascular Disorders","Brain Disorder",[185,186,187,188],"Tenecteplase","Fibrinolytic agents","Thrombectomy","No-reflow","2026-05-14",{"date":191,"type":29},"2026-05-18",{"date":193,"type":29},"2024-06-01",{"date":195,"type":20},"2027-11-30",{"name":197,"class":36},"University of Melbourne",12,{"id":200,"slug":4,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":17,"minAge":205,"maxAge":206,"enrollmentInfo":207,"targetDuration":4,"studyType":48,"phases":209,"briefSummary":210,"conditions":211,"keywords":240,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":275},"100355699","NCT03911388","HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors","Phase 1 Trial of Engineered HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors","Inclusion Criteria:\n\n* Age ≥ 36 months and \\\u003C 22 years\n* Pathologically proven malignant cerebellar brain tumor (including medulloblastoma, glioblastoma multiforme, giant cell glioblastoma, anaplastic astrocytoma, primitive neuroectodermal tumor, ependymoma, atypical teratoid\u002Frhabdoid tumor, germ cell tumor, or other high-grade malignant tumor) which is progressive or recurrent despite standard care including surgery, radiotherapy, and\u002For chemotherapy. A pathologically proven secondary malignant cerebellar tumor without curative treatment options is eligible.\n* Lesion must be ≥ 1.0 cm ≤ 3.0 cm in diameter and surgically accessible as determined by MRI. Larger tumors may be surgically debulked and treated if ≤ 3.0 cm after debulking\n* Patients must have fully recovered from acute treatment related toxicities of all prior chemotherapy, immunotherapy or radiotherapy prior to entering this study.\n* Myelosuppressive chemotherapy: patients must have received their last dose at least 3 weeks prior (or at least 6 weeks if nitrosurea)\n* Investigational\u002FBiologic agents: patients must have recovered from any acute toxicities potentially related to the agent and received last dose ≥ 7 days prior to entering this study (this period must be extended beyond the time during which adverse events are known to occur for agents with known adverse events ≥ 7 days). For viral therapy, patients must have received viral therapy ≥ 3 months prior to study entry and have recovered from all acute toxicities potentially related to the agent.\n* Monoclonal antibodies: The patient must have received last dose ≥ 21 days prior.\n* Radiation: Patients must have received their last fraction of craniospinal radiation (\\>24 Gy) or total body irradiation ≥ 3 months prior to study entry. Patients must have received focal radiation to symptomatic metastatic sites or local palliative radiation ≥ 28 days prior to study entry.\n* Autologous bone marrow transplant: Patients must be ≥ 3 months since transplant prior to study entry.\n* Normal hematological, renal and liver function (absolute neutrophil count \\> 1000\u002Fmm3, platelets \\> 100,000\u002Fmm3, prothrombin time (PT) or partial thromboplastin time (PTT) \\\u003C 1.3 x control, creatinine within normal institutional limits OR creatinine clearance \\>60 mL\u002Fmin\u002F1.73 m2 for patients with creatinine levels above institutional normal, total bilirubin \\\u003C 1.5 mg\u002Fdl, transaminases \\\u003C 3 times above the upper limits of the institutional norm)\n* Patients \\\u003C 16 years, Modified Lansky performance score ≥ 60; patients ≥ 16 years, Karnofsky performance score ≥ 60\n* Patient life expectancy must be at least 8 weeks\n* Written informed consent in accordance with institutional and FDA guidelines must be obtained from patient or legal guardian\n\nExclusion Criteria:\n\n* Any treatment outside the allowable guidelines outlined in section 5.1.\n* Diffuse, widespread, abnormal tumor pattern involving 3 or more lobes of the brain\n* Acute infection, granulocytopenia or medical condition precluding surgery\n* Pregnant or lactating females\n* Diagnosis of encephalitis or CNS infection \\\u003C 3 months prior, or receiving ongoing treatment for encephalitis, CNS infection or multiple sclerosis\n* Tumor involvement which would require ventricular or brainstem inoculation or would require access through a ventricle in order to deliver treatment\n* Required steroid increase within 1 week prior to G207 inoculation or patients requiring \\>2 mg of dexamethasone daily\n* Known HIV seropositivity\n* Concurrent therapy with any drug active against HSV (acyclovir, valacyclovir, penciclovir, famciclovir, gancyclovir, foscarnet, cidofovir) or any immunosuppressive drug therapy (except dexamethasone or prednisone).\n* Other current malignancy\n* Concurrent anticancer or investigational drug","3 Years","21 Years",{"count":208,"type":20},24,[121],"This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-tumor immune response, will also be tested.\n\nFunding Source- FDA OOPD",[212,213,214,127,215,216,217,218,219,220,221,222,223,224,225,226,227,228,229,230,231,232,233,126,130,24,157,234,235,236,237,238,239],"Neoplasms, Brain","Glioblastoma Multiforme","Glioblastoma of Cerebellum","Astrocytoma","Astrocytoma, Cerebellar","Neuroectodermal Tumors","Neuroectodermal Tumors, Primitive","Cerebellar PNET, Childhood","Cerebellar Neoplasms","Cerebellar Neoplasms, Primary","Cerebellar Neoplasm, Malignant","Cerebellar Neoplasm Malignant Primary","Neoplasm Metastases","Neoplasm Malignant","Neoplasms, Neuroepithelial","Neoplasms, Germ Cell and Embryonal","Neoplasms by Histologic Type","Neoplasms, Glandular and Epithelial","Neoplasms, Nerve Tissue","Central Nervous System Neoplasms, Primary","Central Nervous System Neoplasms, Malignant","Nervous System Neoplasms","Medulloblastoma Recurrent","HSV","Virus","Pediatric Brain Tumor","Nervous System Cancer","Primitive Neuroectodermal Tumor (PNET) of Cerebellum",[241,84,213,242,243,244,245,246,247,248,249,250,251,252,253,254,127,255,256,257,258,259,260,261,262,236,235,263,264,265],"Brain Tumor, Recurrent","Gliosarcoma","Medulloblastoma","Anaplastic Astrocytoma","Oligodendroglioma","Rhabdoid Tumor","Ependymoma","Germ Cell Tumor","Choroid Plexus Carcinoma","Cerebral Primitive Neuroectodermal Tumor","Giant Cell Glioblastoma","Atypical teratoid\u002Frhabdoid tumor","Secondary Malignant Cerebellar Tumor","Embryonal Tumor","Oncolytic Virus Therapy","Virotherapy, Oncolytic","Immunotherapy","Central Nervous System Agents","Antineoplastic Agents","Pediatric","Pediatrics","Oncolytic","Herpes Virus","G207","Oncolytic Herpes Virus","2026-05-13",{"date":268,"type":29},"2026-05-15",{"date":270,"type":29},"2019-09-12",{"date":272,"type":20},"2027-09-01",{"name":274,"class":36},"M.D. Anderson Cancer Center",3,{"id":277,"slug":4,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":4,"eligibilityCriteria":281,"healthyVolunteers":11,"sex":17,"minAge":73,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":48,"phases":284,"briefSummary":285,"conditions":286,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":293,"locationsCount":37},"100559941","NCT06570681","Video Call Assisted Assessment of Acute Stroke","Video Call Assisted Assessment of Acute Stroke in Addition to Stroke Scales in a Prehospital Setting: A Cluster Randomised Controlled Trial","Inclusion Criteria:\n\n* Suspected stroke within 24 hours from onset (confirmed with Prehospital Stroke 1 decision tool)\n* Age \\>18 years\n\nExclusion Criteria:\n\n* Suspected stroke more than 24 hours ago\n* In-hospital stroke or private transport to hospital\n* Unconsciousness defined as Glasgow Coma Score (GCS) ≤ 8 (as they cannot be rated)",{"count":283,"type":20},512,[50],"This study aims to investigate whether a live stream video between the on-call neurologist and the emergency medical technicians can increase feasibility and performance of symptom-based prehospital stroke scales.",[53,182,130,157,287,24],"Vascular Diseases","2026-05-11",{"date":189,"type":29},{"date":291,"type":29},"2024-05-27",{"date":131,"type":20},{"name":294,"class":36},"University of Southern Denmark",{"id":296,"slug":4,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":298,"acronym":4,"eligibilityCriteria":299,"healthyVolunteers":11,"sex":17,"minAge":73,"maxAge":45,"enrollmentInfo":300,"targetDuration":4,"studyType":48,"phases":302,"briefSummary":303,"conditions":304,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":37},"100539440","NCT06303869","Deep Brain Stimulation Motor Ventral Thalamus (VOP\u002FVIM) for Restoration of Speech and Upper-limb Function in People With Subcortical Stroke","Inclusion Criteria:\n\n1. Participants must have suffered a single, ischemic, or hemorrhagic stroke more than 6 months before the time of enrollment with dysarthria as a result.\n2. Participants must be between the ages of 18 and 75 years old. (Participants outside this age range may be at an increased medical risk and have an increased risk of fatigue during testing).\n3. English speaker.\n4. Participant must score ≤ 80% in at least 4 categories of the perceptual speech assessment (speech intelligibility, listener effort, speech naturalness, articulatory precision, speech rate, overall voice quality, and\u002For overall speech severity). OR ≤ 80% in at least 3 categories of the perceptual speech assessment AND ≤ 27 on the Communicative Participation Item Bank.\n\nExclusion Criteria:\n\n1. Patients who refuse participation in the study.\n2. Patients with gross anatomical variances in MR imaging or cerebral vascular accidents involving thalamic and cerebellar areas.\n3. Patients with no clinical condition to undergo DBS implantation or highly dependent on anticoagulation therapy.\n4. Patients who cannot undergo pre-operative MRIs or could not complete the pre-operative assessments.\n5. Participants must not have any serious disease or disorder (ex. neurological condition other than stroke, cancer, severe cardiac or respiratory disease, renal failure, etc.) or cognitive impairments that could affect their ability to participate in this study.\n6. Female participants of child-bearing age must not be pregnant, planning to become pregnant for the next 9 months, or breast feeding.\n7. Participants must not be receiving anticoagulants.\n8. Severe claustrophobia.\n9. Participants must not be on anti-spasticity or anti-epileptic medications for the duration of the study.\n10. Participants who have been deemed inappropriate for participation based upon results from the Brief Symptoms Inventory (BSI-18) and discussions with the Principal Investigator and a study physician\n11. Evaluation to sign consent form score \\<12.\n12. MRI contraindications (excluding subjects who are pregnant, who have metal in any portion of their body, have medical complications, cardiac pacemaker, cochlear implant, aneurysm clip, certain IUDs, or known problems of claustrophobia).\n13. Medications with common cognitive side-effects.\n14. Bleeding disorders or platelet dysfunction (e.g., from regular aspirin usage).\n15. Patients must not have any lesions in the lower motoneuron causing flaccid dysarthria.",{"count":301,"type":20},10,[50],"The goal of this study is to verify whether the use of deep brain stimulation can improve motor function of the hand and arm and speech abilities for people following a stroke. Participants will undergo a surgical procedure to implant deep brain stimulation electrode leads. The electrodes will be connected to external stimulators and a series of experiments will be performed to identify the types of movements that the hand and arm can make and how speech abilities are affected by the stimulation. The implant will be removed after less than 30 days. Results of this study will provide the foundation for future studies evaluating the efficacy of a minimally-invasive neuro-technology that can be used in clinical neuro-rehabilitation programs to restore speech and upper limb motor functions in people with subcortical strokes, thereby increasing independence and quality of life.",[53,156,24,157,158],{"date":306,"type":29},"2026-05-08",{"date":308,"type":29},"2025-06-20",{"date":310,"type":20},"2029-12",{"name":312,"class":36},"Jorge Gonzalez-Martinez",{"id":314,"slug":4,"hasResults":11,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":318,"eligibilityCriteria":319,"healthyVolunteers":11,"sex":17,"minAge":320,"maxAge":321,"enrollmentInfo":322,"targetDuration":4,"studyType":48,"phases":324,"briefSummary":325,"conditions":326,"keywords":332,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":345},"100522861","NCT06088121","Study to Evaluate the Efficacy and Safety of ATNC-MDD V1(TMS With Cognitive Training) in Mild Alzheimer's Dementia","Effects of a ATNC MDD-V1 (TMS With Cognitive Training), for the Treatment of Mild Alzheimer Disease: a Randomized, Double-blinded, Placebo-controlled Study","ATC-P001","Inclusion Criteria:\n\n1. Patients who started drug treatment with an acetylcholinesterase inhibitor at least 2 months before participating in the clinical trial and can participate in the clinical trial without changing the dose during the trial period.\n2. Male or female age 60-85 years.\n3. Patients diagnosed with mild stage of Alzheimer's Disease, according to the NIA-AA (2011) diagnosis.\n4. A patient whose dementia was confirmed to be due to Alzheimer's disease by amyloid PET-CT.\n5. MMSE score 21 to 26.\n6. CDR 1 or GDS 3.\n\n   ※ For subjects who are excluded from screening based on criteria 5 or 6, if the investigator judges that the subject is likely to be eligible, one repeat screening may be performed.\n7. A patient who is deemed physically eligible for the clinical trial based on medical records and physical examination.\n8. A patient who is unable to provide voluntary informed consent for the clinical trial due to impaired decision-making capacity, for whom a legally authorized representative provides consent for participation, and who can attend follow-up visits with a caregiver.\n9. Patients who agreed to participate in all 24-week clinical trials.\n10. Patients with normal ability to see and hear letters.\n11. Patients who speak Korean as their mother tongue\n\nExclusion Criteria:\n\n1. Patients with central nervous system (CNS) disorders that may affect cognitive function (such as cerebrovascular diseases including vascular dementia, subdural hematoma, normal pressure hydrocephalus, brain tumors, CNS infections like HIV or syphilis, head trauma, Huntington's disease, Parkinson's disease, etc.) where cognitive decline may be explained by other causes, or in whom dementia types other than Alzheimer's disease are suspected.\n2. Patients who have been unconscious due to brain surgery or concussion, or who have signs or symptoms of cranial pressure elevation on neurologic examination.\n3. History of Epileptic Seizures or Epilepsy.\n4. Patients with a history of drug abuse, including alcohol, in the past 5 years from the time of screening.\n5. Patients with schizophrenia, schizoaffective disorder, bipolar disorder, current major depressive episode, psychosis, panic, post-traumatic stress, severe anxiety, mental retardation, DSM-V disorder.\n6. Patients with abnormal vitamin B12, folic acid deficiency, or thyroid stimulating hormone (TSH) test results that were considered by the investigator to affect or are caused by the severity of dementia.\n7. Patients with metal implants in the head, (i.e. cochlear implants, implanted brain stimulators and neurostimulators, aneurysm clips) with the exception of metal implants.\n8. Cardiac pacemakers.\n9. Implanted medication pumps.\n10. Intracardiac lines.\n11. Patients who are currently taking medications that lower the convulsive seizure threshold.\n12. Significant heart disease.\n13. Patients with severe renal or hepatic impairment※, referring to conditions that significantly affect daily living (e.g., stage 4 chronic kidney disease), with the assessment based on the investigator's judgment.\n14. Contraindication for performing MRI scanning.\n15. Contraindication for performing amyloid PET-CT scanning.\n16. Patients who do not consent to TMS treatment and participation in this clinical trial.\n17. Patients who participated in other clinical trials 3 months before participating in this clinical trial.\n\n    ※ Subjects who participate in non-interventional studies (such as observational studies) that do not affect the subject's disease or symptoms may be enrolled in the study.\n18. Patients with a history of TMS treatment within the last 2 years before participating in this clinical trial.\n19. Patients judged by the investigator to be unsuitable for participation in clinical trials for other reasons.\n\n    ※ If the test subject is unable to visit according to the research plan due to unavoidable personal circumstances during the screening period, it will be treated as a screening dropout, and the patient can participate in the study after re-agreeing according to the future schedule.\n20. Patients with a history of malignant tumors within the last 5 years.\n\n    \\- Participation is possible if more than 5 years have elapsed without recurrence after the decision to be cured (The point of complete removal of the tumor through surgery or the end of chemotherapy, etc.).\n21. Patients who need to take medications suggested in concomitantly contraindicated drugs.","60 Years","85 Years",{"count":323,"type":20},180,[50],"The study tests the effect of the ATNC MDD-V1 on Alzheimer patients' cognitive function. The ATNC MDD-V1 uses non-invasive stimulation of both magnetic and cognitive training.",[327,328,130,24,157,329,330,331],"Alzheimer's Disease","Dementia","Neurodegenerative Diseases","Neurocognitive Disorders","Mental Disorder",[333,334,335,328],"TMS","Cognitive Stimulation","ATNC MDD-V1","2026-04-21",{"date":338,"type":29},"2026-04-23",{"date":340,"type":29},"2023-05-15",{"date":342,"type":20},"2027-06-30",{"name":344,"class":109},"Advanced Technology & Communications",11,{"id":347,"slug":4,"hasResults":11,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":4,"eligibilityCriteria":351,"healthyVolunteers":11,"sex":17,"minAge":352,"maxAge":353,"enrollmentInfo":354,"targetDuration":4,"studyType":48,"phases":356,"briefSummary":357,"conditions":358,"keywords":359,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":37},"100508654","NCT05903235","Mixed Reality and Virtual Reality Technology With Mirror Therapy for Stroke Rehabilitation","Technology-based and Activity-based Design of Mirror Therapy Principles: Two Mixed Reality and Virtual Reality Mirrored-hand Systems for Stroke Rehabilitation","Phase Ⅰ: Design and Development of the VR+MT and MR+MT Systems \\& Feasibility Study\n\nInclusion Criteria:\n\n* diagnosed with unilateral stroke\n* age of 20 to 80 years\n* a baseline Fugl-Meyer Assessment of the Upper Extremity score of 20 to 60\n* able to follow the study instructions and provide the feedback of user experiences verbally\n\nExclusion Criteria:\n\n* diagnosed with global or receptive aphasia\n* the presence of severe neglect\n* the existence of major medical problems or comorbidities that could interfere with upper-limb usage and pain, or disrupt visual or auditory perception\n\nPhase Ⅱ: Validation and Comparison of Clinical Treatment Efficacy\n\nInclusion Criteria:\n\n* diagnosed with unilateral stroke\n* more than 6 months after stroke onset\n* age of 20 to 80 years\n* a baseline Fugl-Meyer Assessment of the Upper Extremity score of 20 to 60\n* able to follow the study instructions\n* capable of participating in the assessment process and treatment program\n\nExclusion Criteria:\n\n* diagnosed with global or receptive aphasia\n* the presence of severe neglect\n* the existence of major medical problems or comorbidities that could interfere with upper-limb usage and pain, or disrupt visual or auditory perception","20 Years","80 Years",{"count":355,"type":20},45,[50],"The specific study aims will be:\n\n1. To design and develop the hardware and software of the VR+MT and MR+MT systems.\n2. To test the feasibility of the VR+MT and MR+MT systems from the patients and to collect the feedback of users with respect to their experiences.\n3. To examine the treatment effects of VR+MT and MR+MT compared to the traditional MT (i.e., control group) in patients with stroke by conducting a randomized controlled trial.\n4. To identify who will be the possible good responders to VR+MT and MR+MT based on their baseline motor functions and mental imagery abilities.",[53,182,24],[360,361,362,363,364],"digital rehabilitation","mixed reality","virtual reality","cerebrovascular accident","mirror visual feedback","2026-03-18",{"date":367,"type":29},"2026-03-20",{"date":369,"type":29},"2024-03-13",{"date":371,"type":20},"2026-07-31",{"name":373,"class":36},"Chang Gung Memorial Hospital",{"id":375,"slug":4,"hasResults":11,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":379,"eligibilityCriteria":380,"healthyVolunteers":11,"sex":17,"minAge":73,"maxAge":381,"enrollmentInfo":382,"targetDuration":4,"studyType":48,"phases":384,"briefSummary":385,"conditions":386,"keywords":389,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":404,"locationsCount":37},"100337803","NCT03678194","Treating Depression on a Day-to-day Basis: Development of a Tool for Physicians Based on a Smartphone Application","Treating Depression on a Day-to-day Basis: Development of a Novel Clinical Tool for Physicians Based on a Smartphone Application, the SMART Project (Smartphones and Mood Disorders, an Application for Research and Treatment)","SMART","Inclusion Criteria:\n\n* Age between 18 and 65 years;\n* Fulfilling the Diagnostic and Statistical Manual version IV (DSM-IV) criteria of depression assessed by the Structured Clinical Interview;\n* Patients started their antidepressant treatment less than 5 days before inclusion;\n* Patient treated in an outpatient setting;\n* Patient informed of the diagnosis of his disease;\n* Informed patient with written consent.\n\nExclusion Criteria:\n\n* A current mental or psychiatric impairment or disease (schizophrenia, bipolar disorder) that required psychotropic medication or inpatient treatment on a psychiatric ward;\n* A history of psychosis, including schizophrenia, bipolar I or bipolar II disorder, and major depressive disorder with psychotic features;\n* Cognitive deficit and not thus being able to comprehend the informed consent and study procedure;\n* Patients with somatic, cognitive or other disorders preventing the use of the device (deafness, impaired vision, illiteracy….);\n* Non-comprehension of the French language","65 Years",{"count":383,"type":20},200,[50],"Testing and validating an e-health (smartphone application) approach to better understand the determinants of day-to-day symptomatology in depression, medication adherence, and treatment efficacy in the goal of maximizing patient care.",[387,388,130,24,157],"Depression","Psychiatric Disorder",[387,390,391,392,393,394,395,396],"Smartphone","Relapse prevention","Mobile support system","eHealth","Ecological","Randomized","Multicentric","2026-03-13",{"date":399,"type":29},"2026-03-16",{"date":401,"type":29},"2020-10-14",{"date":403,"type":20},"2026-12-31",{"name":405,"class":406},"Centre Hospitalier Charles Perrens, Bordeaux","OTHER_GOV",{"id":408,"slug":4,"hasResults":11,"nctId":409,"briefTitle":410,"officialTitle":411,"acronym":4,"eligibilityCriteria":412,"healthyVolunteers":11,"sex":17,"minAge":73,"maxAge":381,"enrollmentInfo":413,"targetDuration":4,"studyType":48,"phases":415,"briefSummary":416,"conditions":417,"keywords":424,"overallStatus":427,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":37},"100627679","NCT07451769","Selective Activation of the Adrenomedullin Receptors in Migraine","Selective Activation of the Adrenomedullin Receptors in Migraine: A Randomized, Double-Blind, Placebo-Controlled Crossover Study","Inclusion Criteria:\n\n1. Written informed consent has been obtained prior to the initiation of any study-specific procedures.\n2. Age ≥18 years at the time of screening.\n3. History of migraine without aura for at least 12 months prior to screening, with a frequency of 1-5 migraine attacks per month, based on medical records and\u002For patient self-report, and diagnosed in accordance with the ICHD-3 criteria.\n\nExclusion Criteria:\n\n1. History of any other primary headache disorder, except for tension-type headache with \\\u003C5 headache days per month, based on ICHD-3 classification.\n2. History of any secondary headache disorder, per ICHD-3 criteria, prior to screening.\n3. Use of prophylactic migraine medication within 30 days or within 5 plasma half-lives (whichever is longer) prior to screening.\n4. Previous use of any therapies targeting the CGRP signaling pathway, including anti-CGRP ligand monoclonal antibodies, anti-CGRP receptor monoclonal antibodies, or small molecule CGRP receptor antagonists.\n5. Known risk of self-harm or harm to others, including a history of suicidal behavior.\n6. Any clinically significant disorder, condition, or disease (other than those permitted in the protocol) that, in the opinion of the investigator, could compromise participant safety or interfere with study procedures or data integrity.\n7. Positive urine pregnancy test at screening or on Day 1 in female participants of childbearing potential.\n8. Pregnancy or breastfeeding, or plans to become pregnant or breastfeed during the study period.\n9. Evidence of current pregnancy or breastfeeding based on self-report or medical records.\n10. Inability or unwillingness to complete all protocol-required visits and procedures, or concerns regarding protocol adherence, as judged by the investigator.",{"count":414,"type":20},26,[50],"Adrenomedullin is a neuropeptide implicated in the pathogenesis of migraine. This study investigates whether its administration, after pre-treatment with erenumab (a CGRP-receptor blocking monoclonal antibody), can trigger migraine attacks in individuals with migraine without aura.",[418,130,24,419,420,421,422,423],"Migraine","Adrenomedullin","Pain","Peptides","Neuropeptides","Signs and Symptoms",[425,426,420],"Migraine Disorders","Adrenomedulin","NOT_YET_RECRUITING","2026-03-05",{"date":430,"type":29},"2026-03-09",{"date":432,"type":20},"2026-03-10",{"date":434,"type":20},"2032-12-20",{"name":436,"class":36},"Danish Headache Center",{"id":438,"slug":4,"hasResults":11,"nctId":439,"briefTitle":440,"officialTitle":440,"acronym":441,"eligibilityCriteria":442,"healthyVolunteers":148,"sex":17,"minAge":443,"maxAge":353,"enrollmentInfo":444,"targetDuration":4,"studyType":48,"phases":446,"briefSummary":447,"conditions":448,"keywords":455,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":482,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":488,"locationsCount":37},"100617877","NCT07324330","Slowing Cognitive Decline in Alpha-synucleinopathies by Enhancing Physical Activity","ALPHA-FIT","Inclusion Criteria:\n\niRBD:\n\n* Age: 50-80 years\n* Polysomnographically confirmed diagnosis of iRBD\n* Maximum of 120 minutes of sports\u002Foutdoor activities per day\n* Less than an average of 10,000 steps per day during the 4-week eligibility and baseline phase\n* Basic smartphone skills\n* Sufficient knowledge of German (native language, C1 or C2)\n* Ownership of a suitable smartphone (minimum screen size 4.6 inches, Android version 9 or iOS version 15 or newer)\n* Consent to be informed of any additional findings\n\nHealthy controls:\n\n* Age: 50-80 years\n* Maximum of 120 minutes of sports\u002Foutdoor activities per day\n* Less than an average of 10,000 steps per day during the 4-week eligibility and baseline phase\n* Basic smartphone skills\n* Sufficient knowledge of German (native language, C1 or C2)\n* Ownership of a suitable smartphone (minimum screen size 4.6 inches, Android version 9 or iOS version 15 or newer)\n* Consent to be informed of any additional findings\n\nExclusion Criteria:\n\niRBD:\n\n* Relevant cardiovascular diseases\n* Problems with dexterity or cognitive impairments that make it difficult to use a smartphone\n* Cognitive impairments that limit the ability to make informed decisions and consent to participate in the study\n* Ownership of one of the following devices: Huawei P8 Lite, Huawei P9 Lite, Xiaomi Mi 6, Huawei P20 Lite (FitBit is not compatible)\n\nHealthy controls:\n\n* Relevant cardiovascular diseases\n* Problems with dexterity or cognitive impairments that make it difficult to use a smartphone\n* Cognitive impairments that limit the ability to make informed decisions and consent to participate in the study\n* Ownership of one of the following devices: Huawei P8 Lite, Huawei P9 Lite, Xiaomi Mi 6, Huawei P20 Lite (FitBit is not compatible)\n* clinically diagnosed iRBD","50 Years",{"count":445,"type":20},130,[50],"α-Synucleinopathies, including Parkinson's disease and dementia with Lewy bodies, are the second most common neurodegenerative diseases. In addition to progressive motor deterioration, cognitive decline is a key element of the non-motor symptom complex of these diseases. Isolated rapid eye movement (REM) sleep behavior disorder (iRBD) indicates an early stage of α-synucleinopathies, even before relevant motor or cognitive disorders are present. Therapeutic interventions in individuals with iRBD therefore have great preventive potential. In particular, increasing physical activity could have a relevant effect on neurodegenerative processes, including the preservation of cognitive functions.\n\nThe aim of the study is therefore to investigate the effects of increased physical activity in everyday life on cognitive functions in individuals with iRBD. In this randomized, double-blind, actively controlled study, an increase in physical activity will be implemented over a period of one year with the help of a motivational smartphone application. The intervention and control conditions are the same as those used in the Slow-SPEED trials, making the connection between the trials concrete. The primary outcome parameter is the change in cognitive performance in a neuropsychological test battery over one year.\n\nEighty individuals with iRBD and 50 age- and gender-matched individuals are being recruited at the University Hospital Bonn and the \"Deutsches Zentrum für Neurodegenerative Erkrankungen\" (DZNE) Bonn (German branch only). In addition to classic neuropsychological tests as the primary endpoint, magnetic resonance imaging (MRI) and blood-based markers of brain aging are being examined as secondary endpoints. This study is in close collaboration with the Slow-SPEED study (https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT06993142). In addition, selected data from three separate trials-Alpha-Fit, Slow-SPEED-NL, and a sister trial in Austria currently in preparation-are planned to be synthesized into a meta-analysis.",[449,450,329,451,24,452,157,453,130,454],"Parkinson Disease","Prodromal Stage","Basal Ganglia Diseases","Synucleinopathies","Cerebral Disorder","Parkinsonian Disorders",[456,457,458,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478,479,480],"intervention","movement","iRBD","prodromal parkinson's","non-pharmacologic","alpha-synucleinopathy","biomarker","cognitive decline","executive function","MRI","lifestyle","prevention","RCT","motor decline","smartphone","smartwatch","accelerometer","scalable","prodromal","PD","Parkinson","Lewy-body","MSA","multiple system atrophy","dementia","2026-01-14",{"date":483,"type":29},"2026-01-16",{"date":485,"type":29},"2025-12-04",{"date":487,"type":20},"2029-12-01",{"name":489,"class":36},"University Hospital, Bonn",{"id":491,"slug":4,"hasResults":11,"nctId":492,"briefTitle":493,"officialTitle":494,"acronym":4,"eligibilityCriteria":495,"healthyVolunteers":11,"sex":17,"minAge":73,"maxAge":381,"enrollmentInfo":496,"targetDuration":4,"studyType":48,"phases":498,"briefSummary":499,"conditions":500,"keywords":512,"overallStatus":427,"whyStopped":4,"lastUpdateSubmitDate":514,"lastUpdatePostDateStruct":515,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":520,"locationsCount":37},"100619142","NCT07340775","Hypersensitivity to Amylin in Post-Traumatic Headache","Hypersensitivity to Amylin in Post-Traumatic Headache: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Age 18 to 65 years of age upon entry into screening\n* History of persistent headache attributed to mild traumatic injury to the head for ≥ 12 months and in accordance with the International Classification of Headache Disorders, 3rd Edition (ICHD-3)\n* ≥ 4 monthly headache days on average across the 3 months prior to screening\n* Provision of informed consent prior to initiation of any study-specific activities\u002Fprocedures\n\nExclusion Criteria:\n\n* \\> 1 mild traumatic injury to the head\n* History of any primary or secondary headache disorder prior to mild traumatic injury to the head (except for infrequent episodic tension-type headache)\n* History of moderate or severe injury to the head\n* History of whiplash injury\n* History of craniotomy\n* History or evidence of any other clinically significant disorder, condition or disease (except for those outlined above) than, in the opinion of the site investigator, would pose a risk to subject safety or interfere with study evaluation, procedures or completion\n* The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior\n* Female subjects of childbearing potential with a positive pregnancy test during any study visit\n* Cardiovascular disease of any kind, including cerebrovascular diseases\n* Hypertension (systolic blood pressure of ≥150 mmHg and\u002For diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day\n* Hypotension (systolic blood pressure of ≤90 mmHg and\u002For diastolic blood pressure of ≤50 mmHg)\n* Initiation, discontinuation, or change of dosing of prophylactic medications within 2 months prior to study inclusion\n* Intake of acute medications (e.g. analgesics, triptans) within 48 hours of infusion start\n* Baseline headache intensity of \\>3 on an 11-point numeric rating scale (0 being no headache, 10 being the worst imaginable headache)\n* Baseline migraine-like headache or self-reported baseline headache that mimics the subjects' usual migraine-like headache",{"count":497,"type":20},21,[50],"Pramlintide is a peptide analogue of human amylin which is a vasoactive substance involved in the pathogenesis of headache. This study investigates whether pramlintide induces migraine-like headache in people with persistent post-traumatic headache (PTH) attributed to mild traumatic brain injury (mTBI).",[501,130,502,157,24,503,423,504,505,420,506,507,508,421,509,510,511],"Headache Disorders, Secondary","Headache Disorders","Neurologic Manifestations","Pathological Conditions, Signs and Symptoms","Post-Traumatic Headache","Peptide Hormones","Hormones","Hormones, Hormone Substitutes, and Hormone Antagonists","Amino Acids, Peptides, and Proteins","Amylin","Pramlintide",[513,420,510],"Post-traumatic headache","2026-01-05",{"date":481,"type":29},{"date":517,"type":20},"2026-02",{"date":519,"type":20},"2028-12",{"name":436,"class":36},{"id":522,"slug":4,"hasResults":11,"nctId":523,"briefTitle":524,"officialTitle":525,"acronym":4,"eligibilityCriteria":526,"healthyVolunteers":11,"sex":17,"minAge":73,"maxAge":381,"enrollmentInfo":527,"targetDuration":4,"studyType":48,"phases":528,"briefSummary":529,"conditions":530,"keywords":533,"overallStatus":427,"whyStopped":4,"lastUpdateSubmitDate":514,"lastUpdatePostDateStruct":534,"startDateStruct":535,"completionDateStruct":536,"leadSponsor":538,"locationsCount":37},"100619143","NCT07340788","Amylin-Induced Migraine Attacks Without Aura","Amylin-Induced Migraine Attacks Without Aura: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Age 18 to 65 years of age upon entry into screening\n* A body weight of 50 to 100 kg\n* History of migraine without aura for ≥12 months and in accordance with ICHD-3\n* Between 1-5 monthly migraine days without aura on average across the 3 months prior to screening\n* Provision of informed consent prior to initiation of any study-specific activities\u002Fprocedures\n\nExclusion Criteria:\n\n* Any history of a primary or secondary headache disorder other than migraine without aura and infrequent episodic tension-type headache\n* Any history of moderate to severe traumatic brain injury\n* Any history of cardiovascular disease, including cerebrovascular diseases\n* Any history of pulmonary disease\n* Any other clinically significant disorders, conditions, or diseases that might impact the safety of the subject or interfere with the study's evaluation, procedures, or completion, aside from those mentioned above. This includes any relevant medical history or evidence that, in the opinion of the site investigator, might pose a risk to the subject or impact the validity of the study results\n* The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior\n* Female subjects of childbearing potential with a positive pregnancy test during any study visit\n* Cardiovascular disease of any kind, including cerebrovascular diseases\n* Hypertension (systolic blood pressure of ≥150 mmHg and\u002For diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day\n* Hypotension (systolic blood pressure of ≤90 mmHg and\u002For diastolic blood pressure of ≤50 mmHg)\n* Abnormalities on the electrocardiogram that, in the opinion of the site investigator, might pose a risk to the subject or impact the validity of the study results\n* Daily use of any medication other than contraceptives\n* Intake of any medication other than contraceptives within 48 hours of infusion start\n* Intake of caffeine, nicotine, and alcohol within 12 hours of infusion start\n* Headache of any intensity within 48 hours of infusion start\n* Migraine attack within 48 hours of infusion start\n* Aura within 48 hours of infusion start",{"count":497,"type":20},[50],"Pramlintide is a peptide analogue of human amylin which is a vasoactive signaling molecule involved in the pathogenesis of migraine. This study investigates whether pramlintide induces migraine attacks without aura in people with migraine without aura.",[531,502,130,157,24,503,423,504,425,532,420,506,507,508,421,509,510,511],"Headache Disorders, Primary","Headache",[418,532,420,510],{"date":481,"type":29},{"date":517,"type":20},{"date":537,"type":20},"2028-10-30",{"name":436,"class":36},{"id":540,"slug":4,"hasResults":11,"nctId":541,"briefTitle":542,"officialTitle":542,"acronym":543,"eligibilityCriteria":544,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":545,"targetDuration":4,"studyType":48,"phases":547,"briefSummary":548,"conditions":549,"keywords":552,"overallStatus":427,"whyStopped":4,"lastUpdateSubmitDate":514,"lastUpdatePostDateStruct":564,"startDateStruct":566,"completionDateStruct":568,"leadSponsor":570,"locationsCount":4},"100618712","NCT07335185","Gravity Stroke System for Recanalization of Large Vessel Occlusion Strokes","GRASSROOT Reg","Inclusion Criteria:\n\n1. Subject has experienced an Acute Ischemic Stroke due to large intracranial vessel occlusion in at least one of the following intracranial vessels: internal carotid artery (ICA), M1and M2 segments of the middle cerebral artery (MCA), basilar, and vertebral artery.\n2. Subject has been or will be treated with Supernova and\u002For Neutron devices as the initial device used to remove the thrombus\n3. Subject is willing to participate in a 90-day follow-up visit.\n\nExclusion Criteria:\n\n* Concurrent participation in another mechanical neurothrombectomy device trial or any other clinical trial with an active treatment arm where the study procedure or treatment might confound the results of the registry.",{"count":546,"type":20},3000,[50],"Supernova and Neutron are endovascular mechanical revascularization devices indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing an acute ischemic stroke within 24 hours of symptom onset or from last known well time.",[53,550,182,130,24,157,551],"Ischemic Stroke","Vascular Disease",[553,554,555,556,557,558,559,560,561,562,53,563],"Mechanical Thrombectomy","Brain","Brain Clot","Cerebral Ischemia","Brain Infarction","Neurovascular Intervention","Revascularization","Reperfusion","Stent Retriever","Supernova","Gravity Medical Technology",{"date":565,"type":29},"2026-01-13",{"date":567,"type":20},"2026-01-01",{"date":569,"type":20},"2030-12-31",{"name":571,"class":109},"Gravity Medical Technology, INC",{"id":573,"slug":4,"hasResults":11,"nctId":574,"briefTitle":575,"officialTitle":575,"acronym":576,"eligibilityCriteria":577,"healthyVolunteers":11,"sex":17,"minAge":73,"maxAge":4,"enrollmentInfo":578,"targetDuration":4,"studyType":48,"phases":580,"briefSummary":581,"conditions":582,"keywords":584,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":594,"lastUpdatePostDateStruct":595,"startDateStruct":597,"completionDateStruct":599,"leadSponsor":601,"locationsCount":37},"100615113","NCT07288385","Investigating the Feasibility of Combining Virtual Reality and Bilateral Transcranial Direct Stimulation to Improve Upper Limb Recovery in Patients With Stroke","bi-tDCS+VR","Inclusion Criteria: 1- Adult participants (over 18 years of age) (Elsner et al., 2020).\n\n2- Patients with a unilateral cerebral infarction or haemorrhage who are at least three months post-stroke (Muller et al., 2021).\n\n3- Adequate mental status confirmed by an MMSE (Arabic version) should be ≥24 (Kim, 2021). ensuring the ability to comprehend and follow instructions.\n\n4- Modified Ashworth scale score \\\u003C 3 (Ögün et al., 2019). 5- Fugl-Meyer assessment (FMA) scores between 29 and 58, indicating moderate impairments (Woytowicz et al., 2017).\n\n\\-\n\nExclusion Criteria: - Visual impairment and severe hemisensory neglect or inattention (Stahl et al., 2019; Fluet1 et al., 2015).\n\n2- Individuals who have aphasia find it difficult to follow instructions (Fluet et al., 2015).\n\n3- Presence of any medical condition that contraindicates the use of non-invasive brain stimulation (Stahl et al., 2019; Learmonth et al., 2021).\n\n4- History of neurological disorders unrelated to stroke or participation in another study.\n\n\\-",{"count":579,"type":20},100,[50],"Following a stroke, the function of the distal upper limb, especially hand and finger movements, is often severely compromised, significantly restricting the ability to carry out daily activities. It is estimated that 55-75% of stroke survivors suffer from motor dysfunction, with upper limb impairments affecting up to 85% of them (Tang et al., 2024). Current rehabilitation approaches, while beneficial, often produce limited gains in hand function, particularly in patients with chronic stroke. Virtual reality (VR) training has emerged as a promising tool in neurorehabilitation, providing repetitive, task-specific, and engaging practice environments that can promote motor learning (Cameirão et al., 2012). tDCS has also shown potential to enhance motor recovery when combined with motor practice (Kang et al., 2016). To date, no studies have directly compared the effectiveness of Bi-tDCS with VR for improving upper limb function after stroke.",[130,24,157,53,583],"Paresis",[585,586,587,588,589,590,591,592,593,53],"ischemic stroke","Hemorrhagic stroke","bi-tDCS","Hemiparesis","Neural activation","Primary motor cortex","NIBS","Non-invasive brain stimulation","Transcranial direct current stimulation","2025-12-29",{"date":596,"type":29},"2025-12-30",{"date":598,"type":29},"2025-12-28",{"date":600,"type":20},"2027-01-30",{"name":602,"class":36},"King Saud University",{"id":604,"slug":4,"hasResults":11,"nctId":605,"briefTitle":606,"officialTitle":606,"acronym":607,"eligibilityCriteria":608,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":609,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":611,"conditions":612,"keywords":614,"overallStatus":427,"whyStopped":4,"lastUpdateSubmitDate":616,"lastUpdatePostDateStruct":617,"startDateStruct":619,"completionDateStruct":621,"leadSponsor":623,"locationsCount":37},"100617013","NCT07313098","Longitudinal Assessment of Protein Markers in the Cerebrospinal Fluid of Patients With Central Nervous System Involvement","HJ-COLOCS","Inclusion Criteria:\n\n1. Patients with a neurological condition diagnosed by a physician requiring cerebrospinal fluid (CSF) collection, through:\n\n   * Neurosurgical procedure (EVD, VP shunt, VSG shunt, tumor surgery, spinal surgery with dural opening, ELD);\n   * Lumbar puncture (LP).\n2. Patients who have (or whose legal guardians, where applicable, have) consented to the storage and reuse of residual biological samples collected during the course of care within the biological collection.\n\nExclusion Criteria:\n\n1\\. Objection by the patient and\u002For the legal guardian, if the patient is a minor, to participation in the study.",{"count":610,"type":20},1000,"In the context of adult pathology, research into biomarkers in cerebrospinal fluid (CSF) has already identified proteins that are commonly used for the early diagnosis of certain neurodegenerative diseases. However, the lack of data available in the literature on pediatric diseases has limited the use of biomarkers in routine practice in children. Importantly, our group has pioneered the establishment of CSF biomarkers in children (e.g., measurement of interferon alpha in CSF by ultra-sensitive digital ELISA), which will undoubtedly be used in routine clinical practice in the future. In light of these arguments, the establishment of a CSF biobank will have major clinical implications, given the rarity of the diseases treated and the number of patients followed.",[613,24],"Neurologic Disorder",[615,24,613],"Cerebrospinal Fluid","2025-12-22",{"date":618,"type":29},"2025-12-31",{"date":620,"type":20},"2026-03-01",{"date":622,"type":20},"2036-01-01",{"name":624,"class":36},"Imagine Institute",{"id":626,"slug":4,"hasResults":11,"nctId":627,"briefTitle":628,"officialTitle":629,"acronym":630,"eligibilityCriteria":631,"healthyVolunteers":11,"sex":17,"minAge":73,"maxAge":4,"enrollmentInfo":632,"targetDuration":634,"studyType":21,"phases":4,"briefSummary":635,"conditions":636,"keywords":644,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":653,"lastUpdatePostDateStruct":654,"startDateStruct":656,"completionDateStruct":658,"leadSponsor":660,"locationsCount":37},"100589453","NCT06954610","Cardiac Assessment for Recurrent Stroke Risk Evaluation in Atrial Fibrillation","CARE-AF: Cardiac Assessment for Recurrent Stroke Risk Evaluation in Atrial Fibrillation","CARE-AF","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Written informed consent (by patient, next of kin or legally authorised representative)\n* Permanent, persistent, or paroxysmal AF previously known or diagnosed during the index hospitalisation\n* Acute (≤7 days), symptomatic ischemic stroke\n\nExclusion Criteria:\n\n* Life expectancy \\\u003C1 year according to the opinion of the investigator\n* Patient is unlikely to attend follow-up visits",{"count":633,"type":20},500,"12 Months","Background\n\nAtrial fibrillation (AF) is the most common cardiac arrhythmia, affecting up to 10% of the elderly. Ischemic stroke is the main complication of AF and cardioembolism is one of the leading causes of ischemic stroke, accounting for approximately one third of cases. Oral anticoagulant therapy (OAC) is a cornerstone in stroke prevention in patients with AF. According to randomized controlled trials of direct oral anticoagulants, a residual risk of ischemic stroke of 1-2% per year for so-called \"breakthrough stroke\" remains, despite adequate intake of OAC. The majority (\\>70%) of these breakthrough strokes are cardioembolic in nature and only a minority are related to medication issues (e.g. non-compliance) or other, non-AF related etiologies. Stroke recurrence risk after such a breakthrough stroke markedly increases to 8-9% per year indicating a particularly high-risk situation. Why OAC fails in certain patients, but not in others remains as poorly understood, as does the reason why the subsequent risk of stroke is so high.\n\nCurrent risk stratification tools, such as the widely used CHA2DS2-VA(Sc)-score, fail to predict stroke risk in such a high-risk cohort, as they were intended to guide the initiation of OAC in low to moderate risk patients. In light of new therapeutic strategies currently being investigated, such as percutaneous left atrial appendage occlusion in patients with breakthrough strokes (ELAPSE - NCT05976685) or in AF-patients deemed high-risk (LAAOS IV - NCT05963698), improved risk stratification and characterization of high-risk AF patients is highly warranted.\n\nSeveral clinical factors, such as those reflected in the CHA2DS2-VA(Sc)-score, and especially a high AF-burden are associated with increased risk of cardioembolic stroke. Several cardiac serum biomarkers are thought to be surrogates not only of cardiac function, but also of cardioembolic risk. Reflecting ventricular and atrial wall tension, myocardial injury, oxidative stress and thrombogenicity, elevated NT-proBNP, MR-proANP, high-sensitive Troponin T and D-Dimers have all been associated with cardioembolic stroke in different AF and non-AF populations. As the main location of thrombus formation, the left atrium (LA) and more specifically its appendage (LAA) are of particular interest in the pathogenesis of cardioembolism. Pronounced LA-enlargement, compared to a normal-sized LA, correlates with an increased risk of cardioembolism in AF-patients. As over 80% of thrombi form within the LAA, several LAA-characteristics, such as slower LAA-flow velocity and larger LAA-orifice area have also been demonstrated to be associated with higher stroke risk. Although there is data on each one of these factors, they have only been investigated in low to moderate risk populations, such as AF-patients without prior stroke, OAC-naïve patients, or even within the general population as a whole. Their role in high-risk AF-patients and in breakthrough stroke is unknown.\n\nHypothesis\n\nThe investigators hypothesize that specific clinical factors, serum cardiac biomarkers and markers of LA- and LAA-morphology and function are associated with breakthrough stroke \u002F OAC-failure and may improve risk stratification.\n\nMethods\n\nCARE-AF is a single-center, prospective cohort study conducted at the Stroke Center of the Inselspital, University Hospital Bern, Switzerland. Patients with an index ischemic stroke and AF (breakthrough and non-breakthrough cases) will be enrolled. The investigators will collect clinical data, serum cardiac biomarkers and echocardiographic indices of the LA and LAA. All patients will receive standardized annual follow-ups until the end of the study, defined as 12 months after the inclusion of the last participant. The primary endpoint is ischemic stroke or systemic embolism during follow-up. First, in a cross-sectional design, the study will assess the association between serum cardiac biomarkers and echocardiographic indices among patients with breakthrough vs. non-breakthrough stroke as index event, applying multivariate regression models. Second, the investigators will perform a longitudinal analysis assessing the association between the variables mentioned above and breakthrough stroke as index event with the primary endpoint, using multivariate Cox regression models. The study aims to enroll a minimum of 500 patients, which provides sufficient power to detect a clinically meaningful adjusted hazard ratio for recurrent stroke of 1.5 with 80% power at an alpha level of 5%.\n\nConclusion\n\nThe results of this project will enhance understanding of the role of specific clinical factors, cardiac serum biomarkers and echocardiographic indices in the residual risk of stroke in patients with AF on anticoagulation therapy. They may improve current risk stratification and have the potential to help guide therapeutic decisions in high-risk situations considering evolving therapeutic possibilities.",[550,637,182,130,24,287,638,639,557,640,641,53,642,643],"Atrial Fibrillation","Arrhythmias, Cardiac","Heart Diseases","Brain Ischemia","Infarction Cerebral","Cardioembolic Stroke","Ischemia",[645,646,647,648,649,650,651,652],"Ischemic stroke","Direct oral anticoagulation","Anticoagulation","Breakthrough stroke","Risk stratification","Atrial fibrillation","Anticoagulant therapy","Direct oral anticoagulant","2025-11-17",{"date":655,"type":29},"2025-11-20",{"date":657,"type":29},"2025-11-04",{"date":659,"type":20},"2028-06-30",{"name":661,"class":36},"Insel Gruppe AG, University Hospital Bern",{"id":663,"slug":4,"hasResults":11,"nctId":664,"briefTitle":665,"officialTitle":666,"acronym":667,"eligibilityCriteria":668,"healthyVolunteers":11,"sex":17,"minAge":73,"maxAge":4,"enrollmentInfo":669,"targetDuration":4,"studyType":48,"phases":671,"briefSummary":672,"conditions":673,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":675,"lastUpdatePostDateStruct":676,"startDateStruct":678,"completionDateStruct":680,"leadSponsor":681,"locationsCount":37},"100583103","NCT06871969","Clinical Evaluation of EEG Device for the Triage of Stroke Patients in the Ambulance","Clinical Evaluation of Pre-hospital Stroke Triage Devices - Electroencephalography","CROSSROADS-EEG","Inclusion Criteria:\n\n* Suspected acute stroke as per judgement of the ambulance personnel.\n* Age 18 years or older.\n* Onset of symptoms (or last seen well) \\\u003C24 hours.\n* Written informed consent by patient or legal representative (deferred).\n\nExclusion Criteria:\n\n\\- Injuries or infections of the scalp in the area of the electrode headset placement.",{"count":670,"type":20},275,[50],"Endovascular thrombectomy (EVT) is the standard treatment for large vessel occlusion (LVO) strokes, but it can only be performed in specialized hospitals. Since ambulance personnel cannot determine if a patient is eligible for EVT, 54% of LVO stroke patients are initially taken to non-EVT-capable hospitals, resulting in an average delay of 1 hour in time-to-EVT in the Netherlands. To reduce this delay, it is crucial for ambulance personnel to identify potential LVO stroke patients and directly transport them to EVT-capable hospitals. Dry electrode electroencephalography (EEG) has shown high diagnostic accuracy for detecting LVO strokes, but in 32% of patients, the EEG signal quality was too poor to analyze.\n\nTo address this issue, TrianecT developed StrokePointer, a portable EEG-based triage device designed to collect and analyze EEG data in patients with suspected acute stroke. The objective of this study is to validate the effectiveness and safety of StrokePointer in detecting LVO stroke among patients with a suspected stroke in the pre-hospital setting.",[550,53,158,287,24,130,157,674],"Cerebrovascular Disease","2025-09-30",{"date":677,"type":29},"2025-10-03",{"date":679,"type":29},"2025-07-01",{"date":137,"type":20},{"name":682,"class":36},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":684,"slug":4,"hasResults":11,"nctId":685,"briefTitle":686,"officialTitle":687,"acronym":688,"eligibilityCriteria":689,"healthyVolunteers":11,"sex":17,"minAge":73,"maxAge":4,"enrollmentInfo":690,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":691,"conditions":692,"keywords":695,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":699,"lastUpdatePostDateStruct":700,"startDateStruct":702,"completionDateStruct":704,"leadSponsor":706,"locationsCount":37},"100525407","NCT06121336","PRecisiOn Medicine In StrokE: Evolution of Plasma Brain-Derived Tau in Acute Stroke","PRecisiOn Medicine In StrokE Study on the Evolution of Plasma Brain-Derived Tau in 100 Patients With Acute Ischemic Stroke","PROMISE-BD-100","Inclusion Criteria:\n\n* clinical diagnosis of acute ischemic stroke\n* presentation within 9 hours of symptom onset\n* large- or medium-vessel occlusion (i.e. an occlusion of the ICA, MCA \\[segments M1-M4\\], ACA \\[segments A1-A3\\], basilar artery, or PCA \\[segments P1 to P3\\]) confirmed by CT or MRI angiography\n* at least 18 years of age\n* written informed consent\n\nExclusion Criteria:\n\n* CT or MRI showing intracranial hemorrhage upon admission\n* A history of ischemic stroke, subarachnoid hemorrhage, intracerebral hemorrhage, subdural hematoma, epidural hematoma, CNS tumor, meningitis, or encephalitis within the last three months\n* severe renal dysfunction (eGFR \\\u003C 30ml\u002Fmin\u002F1.73m2)\n* dementia\n* pre-stroke disability defined as a premorbid modified Rankin Scale score \\> 1",{"count":579,"type":20},"The investigators recently identified Brain-derived tau (BD-tau) as a sensitive blood-based biomarker for brain injury in acute ischemic stroke: in patients with acute ischemic stroke, plasma BD-tau was associated with imaging-based metrics of brain injury upon admission, increased within the first 24 hours in correlation with infarct progression, and at 24 hours was superior to final infarct volume in predicting 90-day functional outcome. While informing on the relation of BD-tau with imaging-based metrics of brain injury, this cross-sectional study was restricted to BD-tau assessments upon admission and at day 2 and could not inform on key characteristics of the evolution of plasma BD-tau, including when exactly it starts to rise, how long it continues to rise, and how it is determined by infarct characteristics as well as comorbidities. Here, the investigators aim to assess plasma BD-tau every hour from admission to 48 hours after onset to evaluate the hypothesis that BD-tau rises immediately after onset and plateaus between three and 48 hours after onset.",[53,693,694,182,130,24,640,157],"Stroke, Acute","Stroke, Ischemic",[53,696,697,698],"Brain injury","Biomarker","Pathophysiology","2025-09-02",{"date":701,"type":29},"2025-09-04",{"date":703,"type":29},"2023-03-01",{"date":705,"type":20},"2026-09-30",{"name":707,"class":36},"Ludwig-Maximilians - University of Munich",{"id":709,"slug":4,"hasResults":11,"nctId":710,"briefTitle":711,"officialTitle":712,"acronym":713,"eligibilityCriteria":714,"healthyVolunteers":11,"sex":17,"minAge":73,"maxAge":45,"enrollmentInfo":715,"targetDuration":4,"studyType":48,"phases":716,"briefSummary":717,"conditions":718,"keywords":726,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":732,"lastUpdatePostDateStruct":733,"startDateStruct":734,"completionDateStruct":736,"leadSponsor":738,"locationsCount":37},"100495499","NCT05731986","Spinal Cord Transcutaneous Stimulation Effect on Blood Pressure in Acute Spinal Cord Injury (SCI)","Neuromodulation of Blood Pressure Using Transcutaneous Spinal Stimulation in Individuals With an Acute Spinal Cord Injury - A Safety, Feasibility and Efficacy Study","SCI","Inclusion Criteria:\n\n* 7-30 days after injury\n* Injury level ≥T2 (thoracic level)\n* American Spinal Injury Association Impairment Scale (AIS) A-C\n* Exhibits at least one of the following hypotensive symptoms:\n\n  1. Baseline hypotension - resting supine or seated SBP \\\u003C 90mmHg;\n  2. SBP drop ≥ 20 mmHg within 5 minutes of assuming seated position;\n  3. Symptoms of orthostasis with a drop of SBP (\\\u003C90mmHg) from supine to sitting.\n\nExclusion Criteria:\n\n* Current illness (e.g., a recent diagnosis of a deep vein thrombosis (DVT) or pulmonary embolism (PE), a pressure injury that might interfere with the intervention, etc.) or infection\n* Ventilator-dependent\n* History of implanted brain\u002Fspine\u002Fnerve stimulators\n* Cardiac pacemaker\u002Fdefibrillator or intra-cardiac lines\n* Significant coronary artery or cardiac conduction disease, a recent history of myocardial infarction\n* Initiated on new cardiac medications within the past 5 days\n* Insufficient mental capacity to understand and independently provide consent\n* Pregnancy\n* Cancer\n* Deemed unsuitable by study physician",{"count":198,"type":20},[50],"The goal of this clinical trial is to evaluate the effect of transcutaneous spinal cord stimulation on blood pressure in individuals with an acute spinal cord injury (within 30 days of injury). Blood pressure instability, specifically orthostatic hypotension (a drop in blood pressure when moving lying flat on your back to an upright position), appears early after the injury and often significantly interferes with participation in the critical rehabilitation time period.\n\nThe main questions it aims to answer are:\n\n1. Can optimal spinal stimulation increase blood pressure and resolve orthostatic symptoms (such as dizziness and nausea) when individuals undergo an orthostatic provocation (a sit-up test)? Optimal stimulation and sham stimulation (which is similar to a placebo treatment) will be compared.\n2. What are the various spinal sites and stimulation parameters that can be used to increase and stabilize blood pressure to the normal range of 110-120 mmHg?\n\nParticipants will undergo orthostatic tests (lying on a bed that starts out flat and then moved into an upright seated position by raising the head of bed by 90° and dropping the base of the bed by 90° from the knee) with optimal and sham stimulation, and their blood pressure measurements will be evaluated and compared.",[719,720,721,157,24,722,723,158,724,725],"Spinal Cord Injuries","Spinal Cord Diseases","Trauma, Nervous System","Hypotension","Orthostatic Hypotension","Acute Spinal Cord Injury","Blood Pressure",[727,728,723,725,729,730,722,731],"Transcutaneous Spinal Cord Stimulation","Spinal stimulation","Neuromodulation","Acute spinal cord injury","Acute inpatient rehabilitation","2025-08-29",{"date":699,"type":29},{"date":735,"type":29},"2023-12-01",{"date":737,"type":20},"2026-08",{"name":739,"class":36},"Kessler Foundation",{"id":741,"slug":4,"hasResults":11,"nctId":742,"briefTitle":743,"officialTitle":744,"acronym":713,"eligibilityCriteria":745,"healthyVolunteers":11,"sex":17,"minAge":73,"maxAge":45,"enrollmentInfo":746,"targetDuration":4,"studyType":48,"phases":748,"briefSummary":749,"conditions":750,"keywords":751,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":732,"lastUpdatePostDateStruct":753,"startDateStruct":754,"completionDateStruct":756,"leadSponsor":758,"locationsCount":37},"100495001","NCT05725499","The Effect of Transcutaneous Stimulation on Blood Pressure in Spinal Cord Injury (SCI)","Neuromodulation of Blood Pressure Using Transcutaneous Spinal Stimulation in Chronic Spinal Cord Injury","Inclusion Criteria:\n\n* Spinal cord injury for greater than or equal to 6 months\n* Injury level ≥ T6 (thoracic level)\n* American Spinal Injury Association (ASIA) Impairment Scale (AIS) A-D\n* Exhibits at least one of the following hypotensive symptoms:\n\n  1. Baseline hypotension - resting supine or seated systolic blood pressure(SBP) \\\u003C 90mmHg;\n  2. SBP drop ≥ 20 mmHg within 5 minutes of assuming seated position;\n  3. Symptoms of orthostasis with a drop of SBP (\\\u003C90mmHg) from supine to sitting\n\nExclusion Criteria:\n\n* Current illness (infection, a pressure injury that might interfere with the intervention, a recent diagnosis of DVT\u002FPE, etc.)\n* Ventilator-dependent\n* History of implanted brain\u002Fspine\u002Fnerve stimulators\n* Cardiac pacemaker\u002Fdefibrillator or intra-cardiac lines\n* Significant coronary artery or cardiac conduction disease, a recent history of myocardial infarction\n* Insufficient mental capacity to understand and independently provide consent\n* Pregnancy\n* Cancer\n* Deemed unsuitable by study physician",{"count":747,"type":20},5,[50],"This project will investigate the effect of spinal cord transcutaneous stimulation on blood pressure in individuals with a chronic spinal cord injury who experience blood pressure instability, specifically, orthostatic hypotension (a drop in blood pressure when moving from lying flat on your back to an upright position).\n\nThe main questions it aims to answer are:\n\n1. What are the various spinal sites and stimulation parameters that normalize and stabilize blood pressure during an orthostatic provocation (70 degrees tilt)?\n2. Does training, i.e., exposure to repeated stimulation sessions, have an effect on blood pressure stability?\n\nParticipants will undergo orthostatic tests (lying on a table that starts out flat, then tilts upward up to 70 degrees), with and without stimulation, and changes in their blood pressure will be evaluated.",[719,722,723,720,158,721,24,157,725],[727,752,723,725,729],"Spinal Stimulation",{"date":699,"type":29},{"date":755,"type":29},"2023-02-01",{"date":757,"type":20},"2026-08-01",{"name":739,"class":36},{"id":760,"slug":4,"hasResults":11,"nctId":761,"briefTitle":762,"officialTitle":763,"acronym":764,"eligibilityCriteria":765,"healthyVolunteers":11,"sex":17,"minAge":73,"maxAge":4,"enrollmentInfo":766,"targetDuration":205,"studyType":21,"phases":4,"briefSummary":768,"conditions":769,"keywords":771,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":779,"lastUpdatePostDateStruct":780,"startDateStruct":782,"completionDateStruct":784,"leadSponsor":786,"locationsCount":37},"100548261","NCT06418698","The Correlation of Intracranial Artery Calcification and Outcomes of Mechanical Thrombectomy","The Prediction of Intracranial Artery Calcification on Adverse Outcomes of Large Vessel Occlusive, Acute Ischemic Stroke Patients After Mechanical Thrombectomy: A Prospective Cohort, Observational Study","CAIS-MT","Inclusion Criteria:\n\n* Male or non-pregnant women with acute stroke symptoms aged over 18 years.\n* Occlusion of the intracranial internal carotid artery, the middle cerebral artery, the anterior cerebral artery, the posterior cerebral artery, basilar artery and intracranial vertebral artery confirmed by CT, MR angiography, or digital subtraction angiography.\n* No absolute contraindication to iodinated contrast media.\n* Planned treatment with EVT by clinical care team.\n* Informed consent obtained from patients or their legal representatives.\n* Willing to be followed up as required by the clinical study protocol.\n\nExclusion Criteria:\n\n* Acute ischemic stroke occurs over 24 hours of time last known well.\n* Neurologic deficits caused by diagnoses other than ischemic stroke, such as intracerebral hemorrhage, subarachnoid hemorrhage, or intracranial tumors.\n* With other underlying factors leading to IAC, such as hyperthyroidism, end-stage renal disease, long-term oral intake of vitamin K antagonist(Warfarin), chronic vitamin D deficiency or overdose, persistent hypomagnesemia, persistent hypercalcemia, persistent hyperphosphatemia and high oral calcium intake.\n* Lack of non-contract CT images on admission and significant artifacts in CT images preventing IAC measurement.\n* Severe renal insufficiency (estimated glomerular filtration rate \\\u003C 30ml\u002Fmin or serum creatinine \\> 220μmol\u002FL (2.5mg\u002Fdl)).\n* Previous cerebrovascular intervention treatment or craniotomy.",{"count":767,"type":20},434,"CAIS-MT is a single-center, prospective cohort study, to evaluate the correlation between outcomes of endovascular treatment(EVT) and intracranial artery calcification(IAC) in patients with acute ischemic stroke due to large or medium vessel occlusion.",[693,550,287,24,157,53,130,182,770],"Intracranial Arterial Calcification",[772,773,774,775,776,777,778],"Acute ischemic stroke","Large vessel occlusion","Mechanical thrombectomy","Endovascular treatment","Agatston score","Prospective cohort study","Intracranial atherosclerotic disease","2025-07-24",{"date":781,"type":29},"2025-07-28",{"date":783,"type":29},"2024-03-28",{"date":785,"type":20},"2029-06",{"name":787,"class":36},"Zhujiang Hospital",""]